Johnna Schifilliti

Johnna Schifilliti is the Director of Operations at Oberland Capital, a New York–based private investment firm focused exclusively on the global healthcare industry. In this role she oversees the firm's internal operations rather than serving as a deal-leading investment professional. Oberland was founded in 2013, manages approximately $3.2 billion in assets (as of December 31, 2025), and runs a team of roughly 25 people specializing in flexible capital structures for life sciences companies.

Before joining Oberland, Schifilliti spent more than seven years at KPMG LLP in the United States. She rose to Associate Director of Marketing within KPMG's private equity practice, where she was responsible for developing and deploying national private equity marketing programs — including budget and strategic planning, credentials and collateral management, thought-leadership development, public relations, event planning, and project management. She began her career as an associate in KPMG's audit practice, spending three years serving higher education and nonprofit clients before moving into the firm's marketing function.

Schifilliti earned a Bachelor of Science in Accountancy from Villanova University. Her combined accounting, audit, and marketing-operations background suits her current operations-leadership remit at Oberland, where she supports a small, specialized investment team.

It is worth noting for any founder using this profile: Schifilliti is an operations and former-marketing executive, not a portfolio decision-maker. Investment decisions at Oberland are driven by the firm's partners and investment team (e.g., managing partners such as Andrew Rubinstein and senior investment staff), so she is not the right point of contact for pitching a deal.

*Note:* Schifilliti herself has no separately published personal investment thesis; the above reflects Oberland Capital's stated strategy, which governs her firm.

• Oberland Capital invests exclusively in the global healthcare and life sciences industry, funding the development and commercialization of healthcare products.
• The firm provides flexible, often non-dilutive capital rather than traditional venture rounds. Its toolkit includes: monetization of royalty streams, acquisition of future product revenues, project-based financing structures, and traditional debt and equity.
• Check sizes run from ~$50 million to $300+ million per investment — a scale aimed at clinical-stage-to-commercial companies, not seed startups.
• The firm targets companies with de-risked or near-commercial assets (approved products, late-stage clinical programs, or marketed therapies) that need capital tailored to a specific product, milestone, or geography.
• Oberland emphasizes deep domain expertise combining scientific and financial knowledge, and structures customized to the partner's needs — a "flexible structure" thesis rather than a fixed-stage mandate.